ASX:VIT

ASX ANNOUNCEMENT

Vitura commences search for director with medical and technology expertise

30 OCTOBER 2026

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura** or the **Company**) advises that the Board has undertaken a review of its composition and skills matrix as part of its ongoing Board renewal and succession planning process.

The review considered the capabilities required to support Vitura's strategic priorities and the next phase of the Company's transformation.

Following this review, the Board has identified an opportunity to further strengthen its composition through the addition of a director with significant medical and technology expertise. The Board believes these capabilities will complement the existing skills and experience of its directors and support the execution of Vitura's Three Horizon Plan – a strategy to drive the business to strong profitability and performance.

As Vitura continues to evolve its healthcare offering and technology-enabled services, the Board considers that additional expertise in these areas will further enhance its ability to oversee strategic execution, innovation and long-term value creation for shareholders.

The Board's Nomination and Remuneration Committee has commenced a formal search process and will undertake a comprehensive assessment to identify the best candidate to join the Board.

As part of its broader governance review, the Board has also considered the ongoing role and purpose of the Company's Industry Advisory Group. Following this review and with the addition of a new director with significant medical and technology experience, the Board has determined to conclude to cease the Industry Advisory Group.

Independently, current Non-Executive Director Shane Tanner has advised the Board that he wishes to retire and has provided 90 days' notice. The Board would very much like to thank Shane for his contribution to Vitura over the past few years. The Board intends to appoint a new director during this transition period.

Vitura's Independent Chair and Non-Executive Director, Robert Iervasi said:

"Our priority is to ensure the Board has the expertise to oversee delivery of the Three Horizon Plan and Vitura's return to strong profitability and performance. As our healthcare offering and technology-enabled services evolve, we are seeking a director who can bring relevant medical and technology expertise to the Board's oversight of strategy and execution"

Vitura will update shareholders when the search process is completed.

ENDS

Authorised by - The Board of Vitura Health Limited.

Contact

Vitura Health Limited

Justin James
CEO
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- www.canview.com.au

Canview was developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration software owned and operated by Vitura. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the in-house integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and

subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au

The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.

• www.cortexa.com.au

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

• www.candor.com.au

The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

• www.releaf.com.au

The Company owns a 42.5% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

• www.cannadoc.com.au

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.